Drug Information

Drug General Information
Drug ID
D0M4YC
Former ID
DAP000504
Drug Name
Disopyramide
Synonyms
Dicorantil; Disopiramida; Disopyramidum; Isorythm; Lispine; Ritmodan; Rythmodan; Disopyramide Free Base; Rythmodan P; D 7644; H 3292; SC 7031; Searle 703; Disopiramida [INN-Spanish]; Disopyramidum [INN-Latin]; Norpace (TN); Rythmodan (TN); Rythmodan P (TN); Rythmodan-La; SC-7031; Xi-Disopyramide; Disopyramide (JP15/USAN/INN); Disopyramide [USAN:BAN:INN:JAN]; Alpha-Diisopropylaminoethyl-alpha-phenylpyridine-2-acetamide; Gamma-Diisopropylamino-alpha-phenyl-alpha-(2-pyridyl)butyramide; Alpha-(2-(Diisopropylamino)ethyl)-alpha-phenyl-2-pyridineacetamide; Alpha-[2-[Bis(1-methylethyl)amino]ethyl]-alpha-phenyl-2-pyridine acetamide; 4-(diisopropylamino)-2-phenyl-2-pyridin-2-ylbutanamide; 4-[di(propan-2-yl)amino]-2-phenyl-2-pyridin-2-ylbutanamide
Drug Type
Small molecular drug
Indication Ventricular arrhythmias [ICD9: 427.1; ICD10:I47.2] Approved [538219], [542176]
Urinary incontinence [ICD9: 788.3; ICD10:N39.3, N39.4, R32] Withdrawn from market [542176], [551871]
Therapeutic Class
Antiarrhythmic Agents
Company
Gd Searle Llc
Structure
Download
2D MOL

3D MOL
Formula
C21H29N3O
InChI
InChI=1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
InChIKey
UVTNFZQICZKOEM-UHFFFAOYSA-N
CAS Number
CAS 3737-09-5
PubChem Compound ID
3114
PubChem Substance ID
9179, 7343341, 7847369, 7979107, 8151982, 10321641, 10520689, 11335664, 11360903, 11363902, 11366464, 11369026, 11371248, 11374266, 11377188, 11461875, 11466294, 11467414, 11484981, 11486067, 11488849, 11490220, 11492339, 11494822, 14777930, 17404965, 24278384, 29222256, 46508226, 47440202, 47736425, 47810710, 47959691, 47959692, 47959693, 48035065, 48110414, 48184952, 49698859, 50068860, 50106174, 50106175, 50106176, 50899557, 53777508, 53786857, 56394974, 57321616, 85085689, 85148360
ChEBI ID
ChEBI:4657
SuperDrug ATC ID
C01BA03
SuperDrug CAS ID
cas=003737095
Target and Pathway
Target(s) Sodium channel protein type 5 subunit alpha Target Info Blocker [535117]
KEGG Pathway Adrenergic signaling in cardiomyocytes
PathWhiz Pathway Muscle/Heart Contraction
Reactome Interaction between L1 and Ankyrins
WikiPathways SIDS Susceptibility Pathways
Cardiac Progenitor Differentiation
References
Ref 538219FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 070101.
Ref 542176(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7167).
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 535117Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol. 2000 Dec;11(12):1320-9.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.